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STUDY QUESTION: Is pubertal timing associated with risk of premenstrual disorders (PMDs) in young adulthood?
SUMMARY ANSWER: Late pubertal development is associated with decreased premenstrual symptom burden and risk of PMDs in
young adulthood.
WHAT IS KNOWN ALREADY: PMDs, including premenstrual syndrome and premenstrual dysphoric disorder, may begin during the
teenage years. Few risk factors in early life have been identified for PMD development.
STUDY DESIGN, SIZE, DURATION: A prospective cohort study of 6495 female participants during 1996–2013.
PARTICIPANTS/MATERIALS, SETTING, METHODS: We included participants from the Growing Up Today Study (GUTS).
Pubertal development was indicated by the timing of menarche, breast and pubic hair growth. Self-reported age at menarche was longitudi-
nally assessed at enrollment (in 1996/2004 for GUTS I/II) and onwards, and classified as early (age  mean  SD, 11.64 years), normative
and late menarche (age  mean þ SD, 13.95 years). Timing of pubic hair and breast growth were assessed multiple times during follow-up
via Tanner scales, and classified into early, normative and late development according to mean § SD. Using a validated questionnaire
based on the Calendar of Premenstrual Experiences, we assessed premenstrual symptoms and identified probable cases of PMDs in 2013.
We examined the associations of timing of pubertal development with premenstrual symptom score and disorders using multivariable
linear and logistic regressions, respectively.
MAIN RESULTS AND THE ROLE OF CHANCE: In 2013 (mean age ¼ 26), 1001 (15.4%) individuals met criteria for a PMD. An in-
verse association was found between age at menarche and premenstrual symptom z-score (b 0.05 per year, 95% CI 0.07 to 0.03)
and risk of PMDs (odds ratio (OR) 0.93 per year, 95% CI 0.88 to 0.99). Compared to individuals with normative menarche, individuals
with late menarche had a lower risk of PMDs (OR 0.73, 95% CI 0.59 to 0.91), while individuals with early menarche had comparable odds
(OR 0.98, 95% CI 0.81 to 1.18). Moreover, early growth of pubic hair was associated with increased premenstrual symptoms (z-score b
0.09 per year, 95% CI 0.02 to 0.17) and PMD risk (OR 1.28, 95% CI 1.04 to 1.56), independent of age at menarche. No associations
were noted for breast development.
LIMITATIONS, REASONS FOR CAUTION: One major limitation is some misclassification of menarche due to recall. We, however,
showed robust association among participants who were premenarcheal at baseline.
VC The Author(s) 2020. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.
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WIDER IMPLICATIONS OF THE FINDINGS: Our findings suggest that pubertal timing, particularly timing of menarche, is
inversely associated with the risk of developing premenstrual symptoms in young adulthood, and that women with later menarche have
significantly lower risk of PMDs. Information on PMDs should be provided to teenage girls and their parents. If these findings are confirmed
in independent populations, prevention strategies and early detection programs may be considered for women with early pubertal
development.
STUDY FUNDING/COMPETING INTEREST(S): The work is supported by the National Institutes of Health and Swedish Research
Council.
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Introduction
Premenstrual disorders (PMDs), including premenstrual syndrome
(PMS) and premenstrual dysphoric disorder (PMDD), are character-
ized by mood and somatic symptoms cyclically occurring in the days
before menstruation (Yonkers and Simoni, 2018). PMS manifests both
as mood and somatic symptoms, while PMDD is primarily dominated
by mood symptoms with significant functional impairment (Yonkers
and Simoni, 2018). With estimated prevalence of 20–30% for PMS
and 2.1–6.4% for PMDD, PMDs affect millions of women around the
world and have a profound impact on quality of life (Cohen et al.,
2002; Qiao et al., 2012; Chumpalova et al., 2020). Although the peak
age of seeking healthcare is in the late 20s, the symptoms of PMDs
may in fact begin during the teenage years (Robinson and Swindle,
2000). Cross-sectional studies have shown that PMDs in adolescents
occur as frequently as in adults (Steiner et al., 2011). A handful of
adulthood risk factors have been identified for PMDs, including dietary
factors (e.g. low calcium and B vitamins) (Bertone-Johnson et al., 2005;
Chocano-Bedoya et al., 2011), obesity (Bertone-Johnson et al., 2010)
and smoking (Bertone-Johnson et al., 2008). Except for childhood
emotional and physical abuse (Bertone-Johnson et al., 2014a), little is
known regarding what early-life factors may play a role in the develop-
ment of PMDs, particularly for those emerging after adolescence.
Although the etiology of PMDs is not fully understood, exposure to
fluctuating sex hormones clearly contributes, as PMDs do not precede
menarche (Yonkers and Simoni, 2018). The elevation and cyclicity of
hormones in puberty modulate the sensitivity of the neuroendocrine
system, which may lead to premenstrual symptoms in some individuals
(Rubinow and Schmidt, 2018). Emerging evidence also supports that
pubertal timing plays an important role in adolescent neurodevelop-
ment through sex hormones (Goddings et al., 2019). It is thus plausible
that earlier and/or later exposure to the elevation and cyclicity of hor-
mones (e.g. early/late menarche) might predispose individuals to dif-
ferential risk of PMDs. So far, most studies have employed cross-
sectional designs and retrospectively collected information on menar-
che, which have yielded conflicting results on the association between
menarche and PMDs (Cohen et al., 2002; Lee et al., 2006; Silva et al.,
2008; Zegeye et al., 2009; Issa et al., 2010; Czajkowska et al., 2015;
Yoshimi et al., 2019). We are not aware of studies investigating other
indicators of pubertal timing, such as pubic hair and breast growth.
Leveraging a large-scale prospective cohort in the USA, here we ex-
amined the association of pubertal development (including timing of
menarche, pubic hair and breast growth) with subsequent risk of
PMDs in young adulthood.
Materials and methods
Study design
The Growing Up Today Study (GUTS) is a prospective cohort study
which includes 15 044 girls and 12 761 boys residing across 50 US
states who were children of participants in the Nurses’ Health Study II
(NHS II) (Rockett et al., 2001). Children recruited in the first phase
(GUTS I; N¼ 16 882) were aged 9–14 years at enrollment in 1996,
while aged 9–16 years at enrollment in 2004 in the second phase
(GUTS II; N¼ 10 923). Briefly, a letter was sent to 40 000 nurses
participating in the NHS II who had at least one child aged 9–14 years
in 1996, inviting their child/children to participate. If the nurse mother
consented, an invitation letter and baseline questionnaire were sent to
their child/children (27 000 (68%)); of those invited 68% of girls
(N¼ 9039) and 58% of boys (N¼ 7843) returned a completed
questionnaire.
A similar approach was taken to recruit participants for GUTS II in
2004, when 21 000 NHS2 participants who gave birth between
1989 and 1993 were sent invitations. Consent was received from
17 280 (82%) women and completed questionnaires were ultimately
received from 68% of girls (N¼ 6005) and 58% of boys (N¼ 4918).
Participants were followed through questionnaires annually during
1996–2001 and then every 2/3 years through 2013. Beginning with
the 2013 questionnaire cycle, the two cohorts were combined and
are now followed together as the GUTS cohort. The response rate
for each questionnaire cycle has ranged from 55% to 87% among girls.
A total of 7896 girls responded to the questionnaire in 2013, when
PMDs were assessed. Girls who missed all items in the assessment of
pubertal development (N¼ 29) or PMDs (N¼ 1372) were excluded,
yielding a final cohort of 6495 participants. Characteristics were highly
comparable between included and excluded participants, including tim-
ing of menarche. Early menarche was experienced by 15.8% of in-
cluded participants vs. 15.1% of non-respondents, while mean age at
menarche was 12.8 vs. 12.7 years (Supplementary Table SI).
This study was approved by the Institutional Review Board of the
Brigham and Women’s Hospital. At enrollment, mothers provided in-
formed consent and the children assented by completing baseline
questionnaires.
Pubertal development
We used the timing of menarche, pubic hair and breast growth as
proxies to study pubertal development. According to the Tanner
stages (Marshall and Tanner, 1969), both pubic hair and breast growth
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are classified into five stages. Pubic hair growth stages range from no
hair (Stage P1; i.e. prepuberty) to hair outside of triangle (Stage P5),
whereas breast growth ranges from flat appearance (Stage B1; i.e.
prepuberty) to areola flattens down (Stage B5). Typically, pubertal
development follows the order of P2> B2> B3> P3> P4> B4>
menarche> P5> B5 (Marshall and Tanner, 1969).
Menarche
Age at menarche was longitudinally assessed on all questionnaires dur-
ing 1996–2003 in GUTS I and 2004–2008 in GUTS II. At enrollment,
3484 (53.9%) girls were reported as premenarchal and 1783 (27.5%)
girls had menarche in the past 2 years. During follow-up, the girls
were repeatedly asked ‘Have you started having menstrual periods?’
and ‘If yes, age when periods began’, by reporting age in years and cal-
endar month at menarche. We derived age at menarche from these
serial questionnaires by using the first report whenever possible. If
month was never reported, we imputed it as 6 months after the
reported integer age. Overall, 6348 (97.7%) participants reported age
at menarche which was normally distributed with a mean of 12.79
(SD, 1.16) years. It was further categorized into early (1 SD below
the sample mean; i.e. 11.64 years), normative (within 1 SD from the
mean; i.e. >11.64 to <13.95 years) and late menarche (1 SD above
the mean; i.e. 13.95 years).
Pubic hair and breast growth
Using the Tanner scales (Marshall and Tanner, 1969), both pubic hair
and breast growth were longitudinally assessed via diagrams during
1996–1998 in GUTS I, while pubic hair growth was additionally
reported in 1999 in GUTS I and during 2004–2008 in GUTS II.
Participants who reported P5/B5 at baseline were excluded from cor-
responding analyses (N¼ 1010 and 219, respectively) as such develop-
ment had ended before enrollment. We always took the first report
for each stage and discarded downstage reports across questionnaires.
Overall, 5387 (82.9%) and 3761 (94.0%) participants reported at least
once for pubic hair and breast stage, respectively. We classified timing
of pubic hair and breast growth into early (if age at any stage from
P2/B2 to P5/B5 was 1 SD below the sample mean), normative
(within 1 SD from the mean) and late development (1 SD above the
mean). Age at each stage is normally distributed and the mean and SD
(along with cutoffs in Supplementary Table SII) of each stage are largely
comparable to the US population (Sun et al., 2002).
Premenstrual disorders
PMDs were assessed in 2013 using a questionnaire based on the
Calendar of Premenstrual Experiences (Mortola et al., 1990); a similar
version has been successfully used in NHS II (Bertone-Johnson et al.,
2007). Briefly, participants were provided with a list of 8 affective and
19 physical/behavioral symptom items and asked if each was experi-
enced in ‘most months of the year for at least several days before
[their] menstrual period begins’ and if so, to rate the severity as none,
mild, moderate or severe. We scored each symptom from 1 to 4,
summed a total score (range 27–108), and converted to z-score for
premenstrual symptoms. While 91% of participants completed all
items, symptoms with missing information were imputed by using a
mean score of other symptoms reported by this individual (<1% of
participants missed >5 out of 27 symptoms).
Participants further rated overall severity for their symptoms and
whether their symptoms caused relationship problems with family/
partner or friends/coworkers, poor work/school performance and in-
creased desire to be alone, in categories of none/minimal, mild, mod-
erate and severe. Individuals were classified as having a PMD if they
met four criteria (Bertone-Johnson et al., 2007): (i) 1 physical/behav-
ioral symptoms and 1 affective symptoms; (ii) overall symptom
severity of moderate/severe, or impact on life activities/relationships
as moderate/severe, or 1 affective symptoms rated as severe;
(iii) symptoms beginning within 14 days, and ending within 7 days, of
the start of menses; and (iv) symptoms absent in the week after men-
ses. The criteria were validated in a cross-sectional study by using daily
symptom diaries (Bertone-Johnson et al., 2014b).
PMDs were further grouped as PMS or probable PMDD (Bertone-
Johnson et al., 2009); criteria for the latter included (i) 1 of 4 severe
affective symptoms including irritability/anger, mood swings/tearful,
depression and anxiety; (ii) 5 of 11 symptom groups including the 4
above and hypersensitivity, desire for aloneness, insomnia, difficulty
concentrating, fatigue, food cravings and/or other physical symptoms;
and (iii) impact on life activities/relationships as moderate/severe. We
aimed to specifically examine PMDs associated with pubertal develop-
ment, which is typically completed by the end of adolescence. We
thus classified PMDs according to the symptom onset below or above
age 20, by asking at what age their symptoms generally began (since
the first period, in the teens, 20s or 30s).
Covariates
Race, maternal marital status and use of multivitamin were reported at
baseline, while paternal educational level was reported by mothers in
1999 in NHS II. Physical activity at baseline was estimated as total
metabolic equivalent (MET) hours per week spent in activities of mod-
erate to vigorous intensity (4 MET) (Ainsworth et al., 2011).
Average number of weekly hours spent in each qualifying activity was
multiplied by its MET, and the products were summed to calculate
weekly MET-hours. Baseline BMI was calculated using self-reported
height and weight, and categorized into underweight, normal, over-
weight and obese according to the extended International Obesity
Task Force (Cole and Lobstein, 2012). Information on adult BMI,
smoking, alcohol drinking, parity and use of hormonal contraceptives
was extracted from 2010/2011 questionnaires. Experiences of child-
hood abuse (including emotional, physical and sexual abuse) at age
<11 years were surveyed in 2007 in GUTS I (Opoliner et al., 2014).
Anxiety and depression are common comorbidities (Kim et al.,
2004). We defined anxiety as a self-reported diagnosis of anxiety or
use of minor tranquilizers, both surveyed in 2013. Depression was de-
fined as a total score >11 using the 10-item Center for Epidemiologic
Studies Depression scale (Opoliner et al., 2014), a self-reported diag-
nosis of depression, or use of antidepressants, all queried in 2013.
Statistical analysis
We estimated bs and 95% CIs for the associations of timing of menar-
che with premenstrual symptoms in z-score using linear regression.
We analyzed age at menarche as a continuous variable, and compared
early/late menarche with normative menarche. Similarly, we estimated
odds ratios (ORs) and 95% CIs of PMDs by using logistic regression.
To reduce potential misclassifications of menarche or PMDs, we
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performed separate sensitivity analyses by restricting to girls premenar-
chal at baseline, to girls who reported months for age at menarche
and to participants who had natural and typical menstrual cycles and
did not use hormonal contraceptives. To illustrate the relationships
with timing, we also assessed the associations of total symptom score
with age at menarche in years.
To shed light on subtypes, we analyzed the associations of timing of
menarche with PMS and probable PMDD, symptom onset before and
after age 20, as well as with and without psychiatric comorbidity, using
multinomial logistic regression which regresses exposures on outcomes
with more than two levels. The direct estimates from this model are
relative risk ratios (equivalent to ORs) (Kwak and Clayton-Matthews,
2002). We further tested the difference between estimates of PMD
subtypes using Wald test. In an additional analysis, we examined asso-
ciations between age at menarche and severity of specific premen-
strual symptoms, and corrected for multiple comparisons using
Bonferroni correction. For the identified symptoms, we further exam-
ined associations with age at menarche by year.
BMI and physical activity are highly correlated with menarche
(Bertone-Johnson et al., 2010), while pubertal development pattern
might be different between the GUTS I and II cohorts. We therefore
examined effect modification of these factors on studied associations.
We examined the correlations of menarche, pubic hair and breast
growth (as categories) using Kendall’s tau coefficients. As additional pu-
bertal markers, we analyzed pubic hair and breast growth by comparing
premenstrual symptoms and PMD risk among women with early/late
development to that among women with normative development.
We developed different models based on a priori hypotheses on po-
tential confounders and mediators (Bertone-Johnson et al., 2005,
2008, 2010; Chocano-Bedoya et al., 2011). We adjusted for cohort
membership and demographic characteristics (year of birth and race)
in Model 1; further adjusted for potential confounders associated with
both pubertal development and PMDs (baseline BMI, physical activity,
paternal educational level, maternal marital status and use of multivita-
min) in Model 2; and additionally adjusted for risk factors for PMDs
(recent smoking, alcohol drinking and use of hormonal contraceptives)
in Model 3. We performed an additional analysis of menarche by
adjusting for childhood abuse (limited to GUTS I) as Model 4. Physical
activity was treated as continuous, while others were categorized as
showed in Table I. In analyses of pubic hair/breast growth, we also
applied additional adjustment for age at menarche.
Data were prepared in SAS (version 9.4) and analyzed in Stata (ver-
sion 12.1). P< 0.05 was considered for statistical significance.
Results
In 2013 (mean age¼ 26§ 3.5 years; Supplementary Fig. S1), 1001
(15.4%) individuals met criteria for a PMD. Among them, 694 (69.3%)
reported symptom onset before age 20. Compared to individuals
without PMDs, individuals with a PMD were less physically active at
baseline, and were more likely to smoke and less likely to use hor-
monal contraceptives in 2010/11 (Table I). Individuals with PMDs
were more likely to report comorbid anxiety and depression
symptoms.
Menarche
Across different multivariable models, we found a robustly inverse as-
sociation between age at menarche and total premenstrual symptom
z-score (b 0.05 per year, 95% CI 0.07 to 0.03, P< 0.001, in the
full model; Table II). Specifically, compared to individuals with norma-
tive age at menarche, higher premenstrual symptom score was noted
in individuals with early menarche (b 0.07, 95% CI 0.00 to 0.14,
P¼ 0.045), whereas lower symptom score was suggested for late
menarche (b 0.07, 95% CI 0.14 to 0.00, P¼ 0.05). Moreover, we
observed an inverse association of age at menarche with PMDs (OR
0.93 per year, 95% CI 0.88 to 0.99, P¼ 0.03). The association was
most notable for late menarche, which was associated with lower risk
of PMDs (OR 0.73, 95% CI 0.59 to 0.91, P¼ 0.006); in contrast, indi-
viduals with early menarche did not have higher risk of PMDs (OR
0.98, 95% CI 0.81 to 1.18, P¼ 0.81). Additional adjustment for child-
hood abuse did not modify the associations in GUTS I (Supplementary
Table SIII). Greater effect sizes were observed in analyses limited to
girls who were premenarchal at baseline, whereas largely comparable
results were yielded when excluding imputed months at menarche,
and when restricting to individuals with natural and normal menstrual
cycles (Supplementary Table SIV).
By analyzing age at menarche by year, such a pattern was also con-
firmed for premenstrual symptom score (Fig. 1). Although PMD risk
was inversely associated with age at menarche beyond 11 years, no
risk increase was found when age at menarche was <11 years.
In subtype analyses, largely similar associations were found between
probable PMDD and PMS, as well as between disorders with and
without comorbidity (Table III). Stronger associations of age at menar-
che and late menarche were noted for early-onset PMDs (symptoms
onset <age 20) compared to associations with disorders emerging af-
terwards (P for difference< 0.05; Table III). We also showed that age
at menarche was inversely associated with premenstrual nausea, acne,
diarrhea/constipation, fatigue, anxiety/nervousness (bs from 0.04 to
0.06; corrected P< 0.05; Supplementary Table SV). A similar pattern
was noted for these identified symptoms by age at menarche analyzed
with indicator variables for each age category (<11, yearly from 11 to
14 and 15 years; Supplementary Fig. S2). In stratified analyses, the
associations of age at menarche with risk of PMDs were largely com-
parable across cohort membership, baseline and adult BMI, and physi-
cal activity (Supplementary Table SVI).
Pubic hair and breast growth
Pubic hair and breast growth were highly correlated (r¼ 0.572,
P< 0.001), and both were moderately correlated with timing of men-
arche (pubic hair: r¼ 0.328, P< 0.001; breast: r¼ 0.348, P< 0.001).
Compared with normative pubic hair development, early development
was associated with higher premenstrual symptom z-score (b 0.11,
95% CI 0.04 to 0.18, P¼ 0.001; Table IV), while late development
appeared associated with a non-significantly lower symptom score
(b 0.03, 95% CI 0.10 to 0.04, P¼ 0.39). Similarly, higher risk of
PMDs was observed in individuals with early pubic hair development
(OR 1.32, 95% CI 1.09 to 1.61, P¼ 0.005), whereas individuals with
late development displayed no increased risk of PMDs. Additional
adjustment for age at menarche minimally altered associations. A
weak inverse association was suggested between timing of breast
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Table I Age-standardized characteristics of women with
and without premenstrual disorders, N (standardized %a)







Total number 5494 1001
Age at menarche, years 12.81§ 1.17 12.68§ 1.09
Age at survey in 2013, years 26.0§ 3.5 25.7§ 3.5
Year of birth
1981–1985 2467 (44.9) 399 (39.9)
1986–1990 1986 (36.1) 410 (41.0)
1991–1995 1041 (18.9) 192 (19.2)
Cohort membership
GUTS I 3419 (61.6) 582 (61.6)
GUTS II 2075 (38.4) 419 (38.4)
Race
White 5143 (93.6) 940 (93.8)
Others 351 (6.4) 61 (6.2)
Baseline assessmentb
Maternal marital status
Not married 427 (7.8) 79 (7.8)
Married 4851 (88.3) 878 (87.8)
Unknown 216 (3.9) 44 (4.4)
Paternal educational level
High school or below 1575 (28.6) 309 (30.9)
College 1732 (31.6) 319 (31.8)
Postgraduate 1838 (33.5) 304 (30.5)
Unknown 349 (6.3) 69 (6.9)
Use of multivitamin
No 3121 (56.8) 570 (57.0)
Yes 2373 (43.2) 431 (43.0)
BMI
Underweight 595 (10.8) 80 (8.0)
Normal 3966 (72.2) 723 (72.1)
Overweight 754 (13.7) 160 (16.1)
Obese 179 (3.3) 38 (3.9)
Moderate/vigorous physical
activity (MET*hours/week)
77.4§ 55.9 75.0§ 55.0
Recent assessmentc
Smoking
Never 4343 (79.0) 716 (71.7)
Former 293 (5.4) 79 (7.5)
Current 858 (15.6) 206 (20.8)
Alcohol drinking
No 1484 (27.1) 280 (27.3)
Monthly 1910 (34.7) 312 (31.4)
Weekly 1598 (29.1) 298 (29.8)











0 4754 (86.6) 848 (84.5)
1þ 370 (6.7) 69 (7.3)
Unknown 370 (6.8) 84 (8.2)
Use of hormonal contraceptives
No 2696 (49.1) 553 (55.1)
Yes, with menstruation 2101 (38.2) 293 (29.4)
Yes, without menstruation 327 (5.9) 71 (7.3)
Unknown 370 (6.8) 84 (8.2)
Childhood abuse (GUTS I only)
No 2690 (48.5) 421 (44.7)
Yes 727 (13.1) 161 (16.9)
Unknown 2 (0.04) 0
Comorbiditiesd
Anxietye
No 4613 (84.0) 759 (75.8)
Yes 881 (16.0) 242 (24.2)
Anxiety diagnosis
No 4663 (84.9) 771 (77.1)
Yes 831 (15.1) 230 (22.9)
Use of minor tranquilizers
No 5324 (96.9) 950 (94.9)
Yes 170 (3.1) 51 (5.1)
Depressionf
No 3879 (70.6) 555 (55.6)
Yes 1615 (29.4) 446 (44.4)
Depression diagnosis
No 4491 (81.8) 736 (73.5)
Yes 1003 (18.2) 265 (26.5)
Use of antidepressants
No 4838 (88.1) 845 (84.3)
Yes 656 (11.9) 156 (15.7)
CES-D Scale
<11 4862 (88.5) 776 (77.8)
>11 632 (11.5) 225 (22.2)
CES-D, Center for Epidemiologic Studies Depression; GUTS, Growing Up Today
Study; MET, metabolic equivalent of task; N, number.
aPercentages of categorical characteristics (except for year of birth) were standard-
ized by year of birth (yearly).
bCharacteristics were assessed at or around the enrollment (i.e. 1996/1997 in GUTS
I and 2004/2005 in GUTS II) except for paternal educational level (in 1999).
cCharacteristics were assessed 2–3 years before the endpoint (i.e. 2010 in GUTS I
and 2011 in GUTS II). If information of smoking or alcohol drinking was not available,
data from questionnaires in 2007/2008 were obtained for GUTS I/GUTS II.
dComorbidities were assessed in 2013 in both GUTS I and GUTS II.
eAnxiety included self-reported diagnosis and use of minor tranquilizers.
fDepression included self-reported diagnosis, use of antidepressants and the CES-D
Scale scored >11.
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Table II. Associations of menarche timing with subsequent risks of premenstrual symptoms (in z-score) and premenstrual
disorders, b (95% CI) or OR (95% CI); Growing Up Today Study, 1996–2013.
Age at menarche, year Early menarche Normative menarche Late menarche
Premenstrual symptoms
Women, N 6348 1025 4370 953
Score, mean (SD) 0.000 (0.999) 0.096 (1.027) 0.002 (1.000) 0.090 (0.956)
Model 1
b (95% CI)a
0.06 (0.08 to 0.04)* 0.09 (0.03–0.16)* 0.00 0.09 (0.16 to 0.02)*
Model 2
b (95% CI)b
0.05 (0.07 to 0.03)* 0.07 (0.00–0.14)* 0.00 0.07 (0.14 to 0.00)
Model 3
b (95% CI)c
0.05 (0.07 to 0.03)* 0.07 (0.00–0.14)* 0.00 0.07 (0.14 to 0.00)
Premenstrual disorders
Events, N (%) 986 (15.5) 168 (16.4) 705 (16.1) 113 (11.9)
Model 1
OR (95% CI)a
0.91 (0.86–0.97)* 1.01 (0.84–1.21) 1.00 0.70 (0.56–0.86)*
Model 2
OR (95% CI)b
0.94 (0.88–1.00)* 0.98 (0.81–1.18) 1.00 0.74 (0.60–0.92)*
Model 3
OR (95% CI)c
0.93 (0.88–0.99)* 0.98 (0.81–1.18) 1.00 0.73 (0.59–0.91)*
Early menarche was defined as age at menarche  mean  SD, whereas late menarche was age  mean þ SD.
N, number; OR, odds ratio.
aIn Model 1, the estimates were adjusted for year of birth and cohort membership in linear and logistic regressions for premenstrual symptoms and disorders, respectively.
bIn Model 2, the estimates were additionally adjusted for race, baseline BMI (categorical), moderate/vigorous physical activity, paternal educational level, maternal marital status and
use of multivitamin.
cIn Model 3, the estimates were additionally adjusted for smoking, alcohol drinking, parity and use of hormonal contraceptives.
*P< 0.05.
Figure 1. Associations of age at menarche with subsequent risks of premenstrual symptoms (in z-score) and disorders.
Growing Up Today Study, 1996–2013. Age at menarche of 12 years was set as the reference. The estimates were adjusted for year of birth,
cohort membership, race, baseline BMI (categorical), moderate/vigorous physical activity, paternal educational level, maternal marital status, and use
of multivitamin, smoking, alcohol drinking, parity and use of hormonal contraceptives. OR, odds ratio.
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..development and premenstrual symptom score, whereas no associa-
tion was observed with PMDs.
Discussion
In this large-scale prospective cohort of participants in the USA, we
showed a consistently inverse association of age at menarche with oc-
currence of subsequent premenstrual symptoms and risk of PMDs in
young adulthood. Moreover, stronger associations were noted for
early-onset PMDs which accounts for near 70% of identified PMDs,
while comparable associations were suggested for probable PMDD
and PMS. We also illustrated similar associations of timing of pubic
hair growth with premenstrual symptoms and PMDs.
Mixed results have been reported on the association between tim-
ing of menarche and PMDs. Four studies reported that individuals with
PMDs appeared to have a younger age at menarche than individuals
without these conditions (Lee et al., 2006; Zegeye et al., 2009; Issa
et al., 2010; Yoshimi et al., 2019). However, none of these results
were statistically significant, except for those in one study that did
not adjust for any confounders. In contrast, one study indicated a
positive association between age at menarche and PMDs
(Czajkowska et al., 2015), whereas two studies suggested a U-
shaped association (i.e. increased risk in individuals with either early
or late menarche) (Cohen et al., 2002; Silva et al., 2008). Most stud-
ies were cross-sectional and retrospectively collected information
on timing of menarche in late adolescence/adulthood, whereas the
only prospective cohort included two follow-ups at age of 13 and
15 (Silva et al., 2008). This may have introduced some recall bias.
Moreover, these studies assessed PMDs using a range of tools.
Some used unvalidated or unknown tools, which may have in-
creased the likelihood of misclassification on symptom experience
and led to over-estimated prevalence (Lee et al., 2006; Silva et al.,
2008; Zegeye et al., 2009; Issa et al., 2010).
With prospectively and annually collected data on menarche,
standardized assessment of PMDs and adjustment for most known
............................................................................................................................................................................................................................
Table III Associations of menarche with subtypes of premenstrual disorders, RRR (95% CI); Growing Up Today Study, 1996–
2013.
Age at menarche, year Early menarche Normative menarche Late menarche
By severitya
PMS
Events, N (%) 846 (13.3) 144 (14.0) 602 (13.8) 100 (10.5)
RRR (95% CI)b 0.93 (0.87–1.00) 0.98 (0.81–1.20) 1.00 0.75 (0.60–0.95)
PMDD
Events, N (%) 140 (2.2) 24 (2.3) 103 (2.4) 13 (1.4)
RRR (95% CI)b 0.93 (0.79–1.09) 0.93 (0.59–1.47) 1.00 0.63 (0.35–1.13)
P for differencec 0.960 0.811 – 0.568
By symptom onset
<Age 20
Events, N (%) 685 (10.8) 129 (12.6) 495 (11.3) 61 (6.4)
RRR (95% CI)b 0.87 (0.81–0.94)* 1.06 (0.86–1.31) 1.00 0.57 (0.43–0.76)*
Age 201
Events, N (%) 301 (4.7) 39 (3.8) 210 (4.8) 52 (5.5)
RRR (95% CI)b 1.08 (0.97–1.20) 0.77 (0.54–1.11) 1.00 1.11 (0.80–1.53)
P for differencec <0.001 0.126 – 0.002
By comorbidityd
No
Events, N (%) 505 (8.0) 89 (8.7) 358 (8.2) 58 (6.1)
RRR (95% CI)b 0.93 (0.85–1.01) 1.04 (0.81–1.33) 1.00 0.73 (0.54–0.98)*
Yes
Events, N (%) 481 (7.6) 79 (7.7) 347 (7.9) 55 (5.8)
RRR (95% CI)b 0.94 (0.86–1.02) 0.92 (0.71–1.19) 1.00 0.74 (0.55–1.01)
P for differencec 0.881 0.469 – 0.924
Early menarche was defined as age at menarche < mean  SD, whereas late menarche was age > mean þ SD.
PMDD, premenstrual dysphoric disorder; PMS, premenstrual syndrome; RRR, relative risk ratio.
aPMS and PMDD were mutually exclusive.
bThe estimates were adjusted for year of birth, cohort membership, race, baseline BMI (categorical), moderate/vigorous physical activity, paternal educational level, maternal marital
status, use of multivitamin, alcohol drinking, parity and use of hormonal contraceptives.
cWe used Wald test to examine the difference between estimates of subtypes.
dComorbidity included anxiety and depression.
*P< 0.05.
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..risk factors, ours is the first study, to our knowledge, to clearly il-
lustrate the inverse association between age at menarche and pre-
menstrual symptoms as well as PMDs. The association, although
not completely linear, is particularly strong and consistent across
analyses of premenstrual symptoms. The relationship with PMD
risk is, however, weaker and complicated (i.e. no increased risk in
individuals with early menarche), likely due to a combined effect of
lower power and residual misclassification of age at menarche.
Indeed, the linear trend is more pronounced in girls who were pro-
spectively followed for menarche since enrollment (i.e. preme-
narcheal girls at baseline). Consistently, we showed a similar
pattern between pubic hair growth and PMDs. Although pubic hair
development is primarily dependent on adrenal androgen produc-
tion, it commonly co-occurs with other pubertal markers (Abreu
and Kaiser, 2016). Collectively, these findings lend some support to
the potential role of pubertal timing in PMD development.
However, we did not observe clear association between breast de-
velopment and PMD risk, although a weak trend was indicated for
premenstrual symptoms. It is also not implausible that the influence
of pubertal timing is stronger on premenstrual symptoms than that
on PMD, which is at the higher end of the symptom spectrum.
One might speculate that individuals with early menarche experi-
enced a greater cumulative number of ovulatory cycles and more
exposures to cyclic hormone fluctuations by a given age, and therefore
are more prone to PMDs than individuals with late menarche. This is,
however, not supported by our findings of stronger associations of
timing of menarche with early-onset PMDs (i.e. symptoms emerged
<age 20). One may also postulate that the association between men-
arche and PMDs is partly driven by comorbid depression, which is
positively associated with early menarche (Galvao et al., 2014). We,
however, showed very similar associations for PMDs with and without
comorbidities.
An alternative explanation is that certain childhood lifestyle may in-
fluence both pubertal timing and PMD development. For instance,
rigorous physical activity may be associated with late menarche
(Moisan et al., 1991), and therefore associated with decreased risk of
PMDs. Although vitamin D-deficiency in childhood may be associated
with early menarche (Villamor et al., 2011), the association of vitamin
D level in adulthood with PMDs has been less consistent (Abdi et al.,
2019). It is also possible that girls who experienced childhood
abuse were are more likely to have early menarche (Boynton-Jarrett
et al., 2013), and therefore increased risk of PMDs (Bertone-Johnson
et al., 2014b). Nevertheless, we have adjusted for these known risk
factors or their proxies for PMDs and observed similar results.
This suggests that our findings are unlikely to be explained by these
factors, although we cannot rule out residual confounding. Time-
............................................................................................................................................................................................................................
Table IV. Associations of pubic hair and breast growth with subsequent risks of premenstrual symptoms (in z-score) and
disorders, b (95% CI) or OR (95% CI); Growing Up Today Study, 1996–2013.
Early development Normative development Late development
Pubic hair growth
Women, N 1180 3005 1127
Premenstrual symptoms
Score, mean (SD) 0.098 (1.047) 0.028 (0.975) 0.077 (0.979)
b (95% CI)a 0.11 (0.04–0.18)* 0.00 0.03 (0.10–0.04)
b (95% CI)b 0.09 (0.02–0.17)* 0.00 0.01 (0.09–0.06)
Premenstrual disorders
Events, N (%) 218 (18.5) 438 (14.6) 161 (14.3)
OR (95% CI)a 1.32 (1.09–1.61)* 1.00 1.00 (0.82–1.23)
OR (95% CI)b 1.28 (1.04–1.56)* 1.00 1.03 (0.83–1.27)
Breast growth
Women, N 716 2236 741
Premenstrual symptoms
Score, mean (SD) 0.058 (1.058) 0.036 (0.987) 0.133 (0.976)
b (95% CI)a 0.05 (0.04–0.14) 0.00 0.06 (0.15–0.03)
b (95% CI)b 0.03 (0.06–0.13) 0.00 0.04 (0.14–0.05)
Premenstrual disorders
Events, N (%) 118 (16.5) 321 (14.4) 96 (13.0)
OR (95% CI)a 1.02 (0.79–1.33) 1.00 1.00 (0.76–1.32)
OR (95% CI)b 0.94 (0.72–1.23) 1.00 1.10 (0.83–1.46)
Pubic hair growth was assessed in 1996–1999 in GUTS I and 2004, 2006, 2008 in GUTS II. Breast growth was measured in 1996–1998 in GUTS I. Early development was defined as
age at any Tanner stage 2–5 of pubic hair/breast growth  mean  SD, whereas late development was age at any Tanner stage 2–5mean þ SD.
aThe estimates were adjusted for year of birth, cohort membership, race, baseline BMI (categorical; if applicable), moderate/vigorous physical activity, paternal educational level, ma-
ternal marital status, use of multivitamin, alcohol drinking, parity and use of hormonal contraceptives.
bThe estimates were additionally adjusted for age at menarche.
*P< 0.05.
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varying diet pattern and physical activity before puberty and abuse be-
tween age 11 and puberty should be adjusted for in future studies.
Additionally, it is not implausible that pubertal timing is biologically
linked to PMDs. Evidence suggest that neurotransmitter gamma-
aminobutyric acid subtype A (GABAA) receptor may play an important
role in PMD development (Yonkers and Simoni, 2018), whereas the
gradual activation of GABAA receptors expressed on gonadotropin-
releasing hormone neurons may be key to pubertal onset and devel-
opment (Herbison, 2016). Future research on GABAA receptors might
help explain the link between pubertal development and PMDs.
Because both premenstrual symptoms and menarche timing are herita-
ble (Jahanfar et al., 2011; Day et al., 2017), it is also possible that they
share common genes. Future research is needed to unravel the under-
lying mechanisms.
Our study had several limitations. First, some misclassification of
menarche, especially early menarche, may have persisted, as 46.1%
of participants had already experienced menarche at baseline.
Reassuringly, data suggest that age at menarche is recalled accu-
rately when the recall interval is <2 years (Koo and Rohan, 1997),
which applies to >80% of our participants. Also, robust associa-
tions were observed in analyses limited to girls premenarcheal at
baseline. Greater misclassification is expected for pubic hair/breast
growth, particularly for late development, as we assessed Tanner
stage at the time of survey completion, rather than when the stage
began. This may partly explain the complicated pattern noted for
late public hair/breast growth. Classification errors may also exist
for B2/B3, which is preferably assessed by breast palpation, espe-
cially for overweight girls. This may explain the overall null associa-
tion with breast development. Moreover, individuals may have
different sensitivity in noticing or reporting symptoms, which could
lead to some misclassification of PMDs. However, we would expect
this to be non-differential with respect to pubertal timing and only
to attenuate findings, rather than explain observed associations.
Furthermore, by necessity, we excluded a significant number of par-
ticipants who did not provide data on PMDs in 2013, due to the re-
duced participation rate 18 years after the baseline. While bias
could emerge if loss-to-follow-up varied by exposure status, we
found that baseline characteristics and age at menarche were
largely comparable between participants included in the analysis
and women not providing information on PMDs in 2013. Thus, it is
unlikely that participation was differentially related to both timing of
menarche and PMDs. Last, only 68% of invited girls were enrolled
in GUTS. Differences in characteristics of girls who joined vs. did
not join may limit the generalizability of our findings to other popu-
lations. For instance, our participants were mostly white and from
middle/upper income-level households. Future studies based on
more racially and socioeconomically diverse populations are
warranted.
In conclusion, our findings suggest that the timing of pubertal devel-
opment, particularly timing of menarche, is inversely associated with
premenstrual symptom burden and PMD risk in young adulthood.
Information on PMDs should be provided to teenage girls and their
parents. If these findings are confirmed in independent populations,
prevention strategies and early detection programs may be considered
for women with early pubertal development.
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